In IPMN-PDAC progression, oncogenic mutations in KRAS and GNAS genes have been observed in 50–80% and 40–70% of IPMN, respectively [164]. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.